Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Bottom Line: BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens.On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation.A recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: Similar results were obtained in an in vivo model of grass pollen allergy (Fig 7, A). Treatment with BM32 reduced allergen-induced basophil activation in sensitized mice significantly for Phl p 1 and Phl p 6 (P < .05) when compared with that seen in PBS-treated mice. A reduction of basophil activation was noted also for Phl p 5 stimulation (Fig 7, B).
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.